Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5R03CA173822-02 Interpret this number
Primary Investigator: Bernatsky, Sasha
Organization: Mcgill University Health Ctr Res Inst
Project Title: Cancer Risk: Advancing Knowledge in Systemic Rheumatic Disease
Fiscal Year: 2014


DESCRIPTION (provided by applicant): 7.0 Project Summary/Abstract Links between chronic disease and cancer risk have been emphasized at various levels, including the World Health Organization. In terms of susceptibility to cancer, individuals with systemic lupus (SLE) have been shown to have distinct cancer risk profiles. Compared to the general population, current data indicate a slight increase in cancer in SLE overall. Within these data, the most evident increased risk is of hematologic cancers, specifically non-Hodgkin lymphoma. In contrast, certain cancers, such as breast, endometrial, and ovarian cancers, may have a decreased risk in persons with SLE, according to recent data. Though, in the past 10 years, a lot has been learnt regarding cancer risk in SLE, much remains unknown. Potentially, both SLE activity itself, and some of the drugs used to treat it, might serve as risk factors for certain malignancies; however, potentially some agents could protect against other cancer types, e.g. breast cancer. Though evidence points to a link between SLE and a decreased risk of breast cancer, the etiology behind this association is unknown. This provides further motivation for more research in this complex field. The primary objectives of our application are: 1. To describe breast cancer cases from an large SLE cohort, with respect to demographics and histology. 2. To assess the importance of drug exposures in persons SLE, regarding breast cancer risk. Here we will estimate the effects of selected medication exposures, adjusting for demographics, reproductive history, smoking and other clinical factors (SLE duration and activity). As secondary objectives, we will determine 1 and 5 year survival rates in the SLE patients who developed breast cancer. Our analyses will be based on data obtained from our multi-site international cohort study of over 16,000 SLE patients. Cancer cases have been ascertained via tumor registry linkage. Relevance: By studying a population like women with SLE, who have such a striking decreased risk of breast cancer, we may learn lessons that can be used to better understand interactions between various risk factors for cancer in the general population. Our project acknowledges that cancer etiology is multi-factorial, and will provide a better understanding of how different factor modify and interact in cancer pathogenesis. Our application answers to several high-priority areas in cancer epidemiology research identified by NIH and the National Cancer Institute, including identification of risk/susceptibility factors, and clinical and translational epidemiolog.


Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
Authors: Bernatsky S. , Ramsey-Goldman R. , Petri M. , Urowitz M.B. , Gladman D.D. , Fortin P.R. , Yelin E.H. , Ginzler E. , Hanly J.G. , Peschken C. , et al. .
Source: The Journal of rheumatology, 2018 Mar; 45(3), p. 393-396.
EPub date: 2018-01-15.
PMID: 29335347
Related Citations

Breast cancer in systemic lupus.
Authors: Bernatsky S. , Ramsey-Goldman R. , Petri M. , Urowitz M.B. , Gladman D.D. , Fortin P.R. , Ginzler E. , Romero-Diaz J. , Peschken C. , Jacobsen S. , et al. .
Source: Lupus, 2017 Mar; 26(3), p. 311-315.
EPub date: 2016-09-30.
PMID: 27687028
Related Citations

DNA-damaging autoantibodies and cancer: the lupus butterfly theory.
Authors: Noble P.W. , Bernatsky S. , Clarke A.E. , Isenberg D.A. , Ramsey-Goldman R. , Hansen J.E. .
Source: Nature reviews. Rheumatology, 2016 Jul; 12(7), p. 429-34.
EPub date: 2016-03-24.
PMID: 27009542
Related Citations

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients.
Authors: Ramsey-Goldman R. , Brar A. , Richardson C. , Salifu M.O. , Clarke A. , Bernatsky S. , Stefanov D.G. , Jindal R.M. .
Source: Lupus science & medicine, 2016; 3(1), p. e000156.
EPub date: 2016-06-06.
PMID: 27335659
Related Citations

Malignancies in systemic lupus erythematosus: a 2015 update.
Authors: Goobie G.C. , Bernatsky S. , Ramsey-Goldman R. , Clarke A.E. .
Source: Current opinion in rheumatology, 2015 Sep; 27(5), p. 454-60.
PMID: 26125105
Related Citations

Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta.
Authors: Bernatsky S. , Smargiassi A. , Johnson M. , Kaplan G.G. , Barnabe C. , Svenson L. , Brand A. , Bertazzon S. , Hudson M. , Clarke A.E. , et al. .
Source: Environmental research, 2015 Jul; 140, p. 474-8.
EPub date: 2015-05-16.
PMID: 25988990
Related Citations

Non-lymphoma hematological malignancies in systemic lupus erythematosus.
Authors: Lu M. , Bernatsky S. , Ramsey-Goldman R. , Petri M. , Manzi S. , Urowitz M.B. , Gladman D. , Fortin P.R. , Ginzler E.M. , Yelin E. , et al. .
Source: Oncology, 2013; 85(4), p. 235-40.
EPub date: 2013-10-02.
PMID: 24107608
Related Citations

Breast cancer in systemic lupus erythematosus.
Authors: Tessier Cloutier B. , Clarke A.E. , Ramsey-Goldman R. , Wang Y. , Foulkes W. , Gordon C. , Hansen J.E. , Yelin E. , Urowitz M.B. , Gladman D. , et al. .
Source: Oncology, 2013; 85(2), p. 117-21.
EPub date: 2013-07-25.
PMID: 23887245
Related Citations

Malignancies in systemic lupus erythematosus.
Authors: Kiss E. , Kovacs L. , Szodoray P. .
Source: Autoimmunity reviews, 2010 Feb; 9(4), p. 195-9.
EPub date: 2009-07-27.
PMID: 19643208
Related Citations

Malignancy in systemic lupus erythematosus: what have we learned?
Authors: Bernatsky S. , Ramsey-Goldman R. , Clarke A.E. .
Source: Best practice & research. Clinical rheumatology, 2009 Aug; 23(4), p. 539-47.
PMID: 19591783
Related Citations

Back to Top